




**Supplementary Table S1.** <sup>18</sup>F-FDG PET/CT SUV Uptake according to PET/CT

Injected	SUV-9w (SUV-max)	SUV-12w (SUV-max)
Placebo	-	-
SK-LMS-1	-	Right rear leg (3.556)
SK-LMS-1	Right rear leg (1.969)	Right rear leg (4.264)
SK-LMS-1 sh-Control	-	-
SK-LMS-1 sh-Control	-	Right rear leg (3.653)
SK-LMS-1 sh-Control	Right rear leg (3.129)	Right rear leg (3.438)
SK-LMS-1 sh-Control	-	Right rear leg/Head (skin) (4.188/2.763)
SK-LMS-1 sh-TJP1	-	-
SK-LMS-1 sh-TJP1	-	-
SK-LMS-1 sh-TJP1	-	Head (4.525)
SK-LMS-1 sh-TJP1	Lung (1.281)	-


**Supplementary Table S2.** Primer information for RT-PCR

Gene	Sequence(5'-3')	Genebank Accession No.
TJP1 - F	GGAGAGGTGTTCCGTGTTGT	NM_003257
TJP1 - R	GAGCGGACAAATCCTCTCTG	NM_003257
CSF1 - F	GCCCCGTTTTAACTCCGTTC	NM_000757
CSF1 - R	CGCCTCCACCTGTAGAACAA	NM_000757
GAPDH - F	GGGTGTGAACCATGAGAAGT	NM_001289745
GAPDH - R	GACTGTGGTCATGAGTCCT	NM_001289745





Supplementary Fig. S2. Immunohistochemistry of LMS tumors from animal model with antibodies against Ki67 and F4/80.



Supplementary Fig. S3. Hierarchical clustering of TCGA LMS Transcriptome.